Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Invested Capital data on file, last reported at $167.6 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $167.6 million, up 95.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $167.6 million (up 95.35% YoY), and the FY2025 annual result was $172.9 million, up 82.05% from the prior year.
• Invested Capital eased to $167.6 million in Q1 2026 per IKT's latest filing, from $172.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $172.9 million in Q4 2025 and troughed at -$385381.0 in Q3 2024.
• A 5-year average of $51.0 million and a median of $25.4 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital sank 102.54% in 2024, then soared 19015.9% in 2025.
• A 5-year view of Invested Capital shows it stood at $21.2 million in 2022, then slumped by 46.37% to $11.4 million in 2023, then surged by 736.08% to $95.0 million in 2024, then surged by 82.05% to $172.9 million in 2025, then dropped by 3.06% to $167.6 million in 2026.
• Business Quant data shows IKT's Invested Capital at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.